ADC Antibodies
ADC antibodies act as the navigation system of ADC drugs and are primarily responsible for delivering payloads to target cells.
All Product Categories
-
ADC Antibodies Related Products (135)
Related Products (135)
-
Puxitatug
0 ImagesSynonyms: INT-016; AZD8205 AntibodyPuxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer.
-
YS5
0 ImagesCat. No.: HY-P990586Purity: 98.01%Synonyms: FOR 46/FG-3246 antibodyYS5 (FOR 46/FG-3246 antibody) is an anti-CD46 antibody. YS5 can serve as an ADC Antibody to synthesize the ADC FOR 46/FG-3246. YS5 is applicable to research related to metastatic castration-resistant prostate cancer.
-
Opucolimab
0 ImagesSynonyms: HLX20; HLX43 antibodyOpucolimab (HLX20) is an engineered anti-PD-L1 humanised IgG1 antibody. Opucolimab, when conjugated with camptothecin toxoid, yields the PD-L1-targeting ADC, HLX43 (HY-177439). HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research.
-
Meplazumab
0 ImagesCat. No.: HY-P991501Purity: 98.70%Synonyms: HcHAb18Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a Kd of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer.
-
Risvutatug
0 ImagesSynonyms: HS-20093 Antibody; GSK5764227 AntibodyHS-20093 Antibody (GSK5764227 Antibody) is an antibody targeting B7-H3, which can be used to synthesize the ADC HS-20093. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors.
-
Denintuzumab
0 ImagesSynonyms: hBU 12Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia.
-
Mirzotamab
0 ImagesMirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC).
-
Anti-EphA2 Antibody (1C1)
0 ImagesCat. No.: HY-P990627Purity: 99.9%Synonyms: MEDI-547 antibodyAnti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2 monoclonal antibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma.
-
Becotatug
0 ImagesSynonyms: JMT-101; MRG003 AntibodyBecotatug (JMT-101) is a humanized IgG1 monoclonal antibody targeting epidermal growth factor receptor (EGFR), and serves as the antibody component of the antibody-drug conjugate Becotatug vedotin (HY-171265). Becotatug specifically binds to the extracellular domain of EGFR, induces receptor internalization and degradation, blocks the EGFR signaling pathway, and mediates antibody-dependent cellular cytotoxicity. When conjugated to monomethyl auristatin E (MMAE) (HY-15162) via a valine-citrulline cleavable linker, Becotatug enables targeted delivery of cytotoxic drugs to EGFR-positive tumor cells. Becotatug can be used for research related to non-small cell lung cancer, nasopharyngeal carcinoma, and head and neck squamous cell carcinoma..
-
Naratuximab
0 ImagesSynonyms: Anti-TSPAN26/CD37 Reference Antibody (naratuximab)Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine.
-
Camidanlumab
0 ImagesSynonyms: HuMax-TACCamidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
-
Arcotatug
0 ImagesSynonyms: IBI-343 antibody; HB37A6; TAK-921 AntibodyArcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs.
-
Praluzatamab
0 ImagesSynonyms: CX-191; CX-2009 AntibodyPraluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers.
-
Lifastuzumab
0 ImagesLifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001).
-
Azintuxizumab
0 ImagesAzintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin.
-
FZ-A038
0 ImagesCat. No.: HY-P990896Purity: 99.22%FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729).
-
Ozuriftamab
0 ImagesSynonyms: BA302
-
Ixotatug
0 ImagesSynonyms: TORL-1-23 AntibodyIxotatug (TORL-1-23 Antibody) is a monoclonal antibody targeting claudin-6 (CLDN6) that serves as the antibody component of the ADC drug Ixotatug vedotin (TORL-1-23). Ixotatug is applicable to research related to various cancers including ovarian cancer.
-
Belantamab (FUT8-KO)
0 ImagesCat. No.: HY-P9980APurity: 98.10%Belantamab (FUT8-KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT8-KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin.
